Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Gettinger, Scott N, Dr ; Bazhenova, Lyudmila A, Prof ; Langer, Corey J, Prof ; Salgia, Ravi, Prof ; Gold, Kathryn A, MD ; Rosell, Rafael, Prof ; Shaw, Alice T, MD ; Weiss, Glen J, MD ; Tugnait, Meera, PhD ; Narasimhan, Narayana I, PhD ; Dorer, David J, PhD ; Kerstein, David, MD ; Rivera, Victor M, PhD ; Clackson, Timothy, PhD ; Haluska, Frank G, MD ; Camidge, David Ross, Prof
The lancet oncology, 2016-12, Vol.17 (12), p.1683-1696 [Periódico revisado por pares]England: Elsevier Ltd
Texto completo disponível